AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37386752 — intervention group
Group type: COMPARATOR
Intervention: Control group (Customized healing abutment without CTG)
Number of subjects: 32
Study 37387213 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd)
Number of subjects: 0
Study 37387213 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 37387272 — intervention group
Group type: EXPERIMENTAL
Intervention: Received breast milk at 7 months
Number of subjects: 999
Study 37387272 — intervention group
Group type: COMPARATOR
Intervention: Did not receive breast milk at 7 months
Number of subjects: 999
Study 37387399 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 0
Study 37387503 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 39
Study 37387798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine administration at 1.5 mg/kg
Number of subjects: 0
Study 37387798 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 37388217 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD-Anti-inflammatory diet (IBD-AID) adapted for Puerto Ricans with CD
Number of subjects: 0
Study 37388217 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37388233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (HF-RT) - 40 Gy/15 fractions ± concomitant boost [8 Gy/15 fractions]
Number of subjects: 86
Study 37388233 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (CF-RT) - 50 Gy/25 fractions ± sequential boost [10 Gy/5 fractions]
Number of subjects: 86
Study 37388233 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment using EORTC QLQ-C30 and QLQ-BR23
Number of subjects: 86
Study 37388633 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexitarian diet including approximately three serves of red meat (average of 390 g cooked weight per individual) per week
Number of subjects: 80
Study 37388633 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet including plant-based meat alternatives (350-400 g per individual) per week
Number of subjects: 80
Study 37388640 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma osteoprotegerin (OPG) levels
Number of subjects: 3766
Study 37388640 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma OPG concentrations
Number of subjects: 3766
Study 37388902 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) treatment in EGFR-mutant NSCLC patients with YAP1_High expression
Number of subjects: 0
Study 37388902 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) treatment in EGFR-mutant NSCLC patients with YAP1_Low expression
Number of subjects: 0
Study 37388902 — intervention group
Group type: EXPERIMENTAL
Intervention: YAP1 expression levels
Number of subjects: 0
Study 37388902 — intervention group
Group type: EXPERIMENTAL
Intervention: YAP1_High tumors
Number of subjects: 0
Study 37389016 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanting lungs from deceased donors with hepatitis C virus (HCV) infection
Number of subjects: 10
Study 37389016 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanting HCV-RNA positive lungs
Number of subjects: 10
Study 37389229 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve field stimulation (PENFS) for 6 consecutive weeks
Number of subjects: 30
Study 37389229 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve field stimulation (PENFS)
Number of subjects: 30
Study 37389878 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy (iRARC)
Number of subjects: 305
Study 37389878 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 305
Study 37389891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg)
Number of subjects: 148
Study 37389891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 37389915 — intervention group
Group type: EXPERIMENTAL
Intervention: Purposeful Pathways intervention (augmented treatment condition)
Number of subjects: 50
Study 37389915 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 50
Study 37389917 — intervention group
Group type: EXPERIMENTAL
Intervention: AF 5g (Predilife)
Number of subjects: 79
Study 37389917 — intervention group
Group type: EXPERIMENTAL
Intervention: AF 10g (Predilife)
Number of subjects: 79
Study 37389917 — intervention group
Group type: EXPERIMENTAL
Intervention: AF 5g (Predilife) + 10g MTDx
Number of subjects: 79
Study 37389917 — intervention group
Group type: COMPARATOR
Intervention: PP 5g + 10g MTDx
Number of subjects: 79
Study 37389933 — intervention group
Group type: EXPERIMENTAL
Intervention: m-RESIST intervention (smartwatch, mobile app, web-based platform, tailored therapeutic program)
Number of subjects: 39
Study 37389933 — intervention group
Group type: EXPERIMENTAL
Intervention: m-RESIST intervention
Number of subjects: 39
Study 37389935 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST-chatbot
Number of subjects: 528
Study 37389935 — intervention group
Group type: COMPARATOR
Intervention: HIVST-OIC
Number of subjects: 528
Study 37390074 — intervention group
Group type: EXPERIMENTAL
Intervention: Silverman and Andersen index (SA index)
Number of subjects: 44
Study 37390280 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic discectomy
Number of subjects: 470
Study 37390310 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 529
Study 37390310 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 529
Study 37390310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 529
Study 37390360 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 113
Study 37390360 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 113
Study 37390376 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37390764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib (RAM + ERL)
Number of subjects: 386
Study 37390764 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib (PBO + ERL)
Number of subjects: 386
Study 37390799 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K Antagonist (VKA)
Number of subjects: 300
Study 37390799 — intervention group
Group type: COMPARATOR
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 300
Study 37390799 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 300
Study 37390799 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban, Apixaban, Edoxaban
Number of subjects: 300
Study 37390800 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA with a mutated allelic frequency (MAF) cut-off of 20%
Number of subjects: 412
Study 37390800 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ctDNA MAF and carcinoembryonic antigen levels
Number of subjects: 412
Study 37390805 — intervention group
Group type: EXPERIMENTAL
Intervention: Shamba Maisha intervention (US$175 in-kind loan for micro-irrigation pump, seeds, fertilizer, and training sessions)
Number of subjects: 377
Study 37390805 — intervention group
Group type: EXPERIMENTAL
Intervention: Shamba Maisha intervention
Number of subjects: 377
Study 37390836 — intervention group
Group type: EXPERIMENTAL
Intervention: ZPIV (two or three doses administered at days 0, 28, and 196-234)
Number of subjects: 75
Study 37390836 — intervention group
Group type: EXPERIMENTAL
Intervention: ZPIV (third dose)
Number of subjects: 75
Study 37390836 — intervention group
Group type: EXPERIMENTAL
Intervention: ZPIV (two doses)
Number of subjects: 75
Study 37390864 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness resection (EFTR)
Number of subjects: 90
Study 37390864 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 90
Study 37390980 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Olaparib (300 mg orally, twice daily)
Number of subjects: 401
Study 37390980 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab plus Placebo
Number of subjects: 401
Study 37390980 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Olaparib
Number of subjects: 401
Study 37391055 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Gut-directed Hypnotherapy (GDH)
Number of subjects: 362
Study 37391055 — intervention group
Group type: COMPARATOR
Intervention: Digital Muscle Relaxation (MR)
Number of subjects: 362
Study 37391056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg intravenous induction)
Number of subjects: 915
Study 37391056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous 90 mg)
Number of subjects: 915
Study 37391056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous 90 mg q8w)
Number of subjects: 915
Study 37391056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 915
Study 37391367 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily written patient care updates
Number of subjects: 219
Study 37391367 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 219
Study 37391381 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid steroid withdrawal (RSWD)
Number of subjects: 587
Study 37391381 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy
Number of subjects: 587
Study 37391470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 37391523 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 78
Study 37391523 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral triangle block (FTB)
Number of subjects: 78
Study 37391523 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 78
Study 37391547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 3872
Study 37391667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study 37391667 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Pirfenidone
Number of subjects: 0
Study 37391729 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative ketamine infusion (intraoperative and postoperative for up to 48 hours)
Number of subjects: 1544
Study 37391729 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (intraoperative and postoperative for up to 48 hours)
Number of subjects: 1544
Study 37391738 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening using a 30-s single-lead electrocardiogram (SL-ECG) during outpatient visits.
Number of subjects: 15393
Study 37391738 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day 12-lead ECGs
Number of subjects: 15393
Study 37391738 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of primary care practitioners (PCPs)
Number of subjects: 15393
Study 37391738 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty regarding AF screening outside of office visits
Number of subjects: 15393
Study 37391773 — intervention group
Group type: EXPERIMENTAL
Intervention: DigiKnowItNews: Teen (educational website)
Number of subjects: 0
Study 37391773 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (no access to DigiKnowItNews: Teen during the study)
Number of subjects: 0
Study 37391828 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-MM group
Number of subjects: 70
Study 37391828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho-k lenses with smaller BOZD
Number of subjects: 70
Study 37391828 — intervention group
Group type: EXPERIMENTAL
Intervention: Total HOAs, total SA, and primary SA
Number of subjects: 70
Study 37391836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-emergency medical service (n = 1544)
Number of subjects: 3531
Study 37391836 — intervention group
Group type: COMPARATOR
Intervention: Conventional physician-based emergency medical service (control) (n = 1676)
Number of subjects: 3531
Study 37391842 — intervention group
Group type: EXPERIMENTAL
Intervention: E-MinD Life programme
Number of subjects: 9
Study 37391938 — intervention group
Group type: COMPARATOR
Intervention: Trifluridine/tipiracil alone (arm A)
Number of subjects: 62
Study 37391938 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus trifluridine/tipiracil (arm B)
Number of subjects: 62
Study 37391938 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR rechallenge (fourth-line therapy)
Number of subjects: 62
Study 37391938 — intervention group
Group type: COMPARATOR
Intervention: Other therapies (fourth-line therapy)
Number of subjects: 62
Study 37391938 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR rechallenge (fourth-line treatment)
Number of subjects: 62
Study 37391938 — intervention group
Group type: COMPARATOR
Intervention: Other therapies (fourth-line treatment)
Number of subjects: 62
Study 37392089 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine (twice-a-week for 4 weeks, then once-a-week for 4 weeks)
Number of subjects: 25
Study 37392210 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome intervention
Number of subjects: 0
Study 37392210 — intervention group
Group type: EXPERIMENTAL
Intervention: Gnotobiotic mouse modeling
Number of subjects: 0
Study 37392210 — intervention group
Group type: EXPERIMENTAL
Intervention: Metagenomic sequence analysis
Number of subjects: 0
Study 37392268 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PrEP
Number of subjects: 119
Study 37392268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 119
Study 37392268 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure experiences
Number of subjects: 119
Study 37392274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus muscle stretching technique
Number of subjects: 7
Study 37392274 — intervention group
Group type: COMPARATOR
Intervention: Standard medial rectus recession (retrospective control)
Number of subjects: 7
Study 37392342 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination targeting Latino ethnic origin
Number of subjects: 82
Study 37392342 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination targeting undocumented residency status
Number of subjects: 82
Study 37392342 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination targeting sexual orientation
Number of subjects: 82
Study 37392342 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping self-efficacy for problem solving
Number of subjects: 82
Study 37392342 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping self-efficacy for stopping unpleasant emotions/thoughts
Number of subjects: 82
Study 37392342 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping self-efficacy for getting social support
Number of subjects: 82
Study 37392342 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of coping self-efficacy
Number of subjects: 82
Study 37392597 — intervention group
Group type: EXPERIMENTAL
Intervention: UB-311 (Q3M arm)
Number of subjects: 43
Study 37392597 — intervention group
Group type: EXPERIMENTAL
Intervention: UB-311 (Q6M arm)
Number of subjects: 43
Study 37392597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo arm)
Number of subjects: 43
Study 37392783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocyte donation in patients with UMAs
Number of subjects: 468
Study 37392783 — intervention group
Group type: COMPARATOR
Intervention: Oocyte donation in patients with normal uteri
Number of subjects: 468
Study 37392783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocyte donation in patients with a unicornuate uterus
Number of subjects: 468
Study 37392783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocyte donation in patients with UMAs without surgery
Number of subjects: 468
Study 37392783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocyte donation in patients with a partial septate uterus
Number of subjects: 468
Study 37392789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) 160/150/50 μg, once-daily (o.d.)
Number of subjects: 3065
Study 37392789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) pooled (160/150/50 μg and 80/150/50 μg)
Number of subjects: 3065
Study 37392789 — intervention group
Group type: COMPARATOR
Intervention: High-dose Mometasone/indacaterol (MF/IND) 320/150 μg, once-daily (o.d.)
Number of subjects: 3065
Study 37392789 — intervention group
Group type: COMPARATOR
Intervention: High-dose Fluticasone/salmeterol (FLU/SAL) 500/50 μg, twice-daily (b.i.d.)
Number of subjects: 3065
Study 37392954 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EUS-GBD) with lumen-apposing metal stents (LAMSs)
Number of subjects: 48
Study 37393120 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor+dexamethasone plus pomalidomide (SPd), n = 23
Number of subjects: 62
Study 37393120 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor+dexamethasone plus bortezomib (SVd), n = 16
Number of subjects: 62
Study 37393120 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor+dexamethasone plus carfilzomib (SKd), n = 23
Number of subjects: 62
Study 37393120 — intervention group
Group type: COMPARATOR
Intervention: selinexor+dexamethasone (Sd)
Number of subjects: 62
Study 37393237 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted inactivated influenza vaccine (aIIV3)
Number of subjects: 680
Study 37393237 — intervention group
Group type: COMPARATOR
Intervention: High-dose inactivated influenza vaccine (HD-IIV3)
Number of subjects: 680
Study 37393243 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Advance Directives (PAD)
Number of subjects: 120
Study 37393243 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Health Care Proxy (HCP) role
Number of subjects: 120
Study 37393243 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior registration of PAD
Number of subjects: 120
Study 37393243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic factors (age, gender, education, job, marital status, internet access)
Number of subjects: 120
Study 37393243 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious beliefs (Non-Catholic)
Number of subjects: 120
Study 37393269 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 35
Study 37393269 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study 37393272 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-MetS group
Number of subjects: 52
Study 37393272 — intervention group
Group type: COMPARATOR
Intervention: MetS group
Number of subjects: 52
Study 37393278 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 126
Study 37393278 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification (CP)
Number of subjects: 126
Study 37393359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0
Study 37393359 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 37393415 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT (Clinical Trial No. NCT04499079)
Number of subjects: 0
Study 37393415 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME (Clinical Trial No. NCT04135703)
Number of subjects: 0
Study 37393415 — intervention group
Group type: EXPERIMENTAL
Intervention: LeSA (Clinical Trial No. NCT04678960)
Number of subjects: 0
Study 37393483 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise and eating fruits and vegetables
Number of subjects: 255
Study 37393483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination schedules
Number of subjects: 255
Study 37393513 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of nusinersen
Number of subjects: 6
Study 37393513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen levels in cerebrospinal fluid
Number of subjects: 6
Study 37393568 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet Anastomosis System (MS) for side-to-side duodeno-ileostomy diversion
Number of subjects: 5
Study 37393586 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pre-diagnostic low-fat dairy intake
Number of subjects: 1812
Study 37393586 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pre- and post-diagnostic low-fat dairy intake
Number of subjects: 1812
Study 37393586 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of high-fat dairy
Number of subjects: 1812
Study 37393658 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone (ACTH) stimulation
Number of subjects: 0
Study 37393691 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (ITZ) and hydroxyitraconazole (ITZ-OH) analysis using a validated LC-MS/MS method.
Number of subjects: 672
Study 37393691 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference testing of over-the-counter and common co-administered medications.
Number of subjects: 672
Study 37393691 — intervention group
Group type: EXPERIMENTAL
Intervention: Incurred sample reanalysis (ISR) at the conclusion of the clinical study.
Number of subjects: 672
Study 37393757 — intervention group
Group type: EXPERIMENTAL
Intervention: High VEGFR2 expression
Number of subjects: 333
Study 37393757 — intervention group
Group type: EXPERIMENTAL
Intervention: High CD34 levels
Number of subjects: 333
Study 37393762 — intervention group
Group type: EXPERIMENTAL
Intervention: KN046 3 mg/kg
Number of subjects: 64
Study 37393762 — intervention group
Group type: EXPERIMENTAL
Intervention: KN046 5 mg/kg
Number of subjects: 64
Study 37393802 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a or IM interferon beta-1a
Number of subjects: 426
Study 37394115 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-B
Number of subjects: 135
Study 37394115 — intervention group
Group type: COMPARATOR
Intervention: CART-A
Number of subjects: 135
Study 37394178 — intervention group
Group type: EXPERIMENTAL
Intervention: FMXIN002 3.2 mg after nasal allergen challenge
Number of subjects: 12
Study 37394178 — intervention group
Group type: EXPERIMENTAL
Intervention: FMXIN002
Number of subjects: 12
Study 37394178 — intervention group
Group type: COMPARATOR
Intervention: EpiPen (0.3 mg)
Number of subjects: 12